肿瘤免疫治疗相关预测生物标志物研究进展

Research progress in predictive biomarkers related to tumor immunotherapy

肿瘤免疫治疗是一种主要针对程序性死亡蛋白-1(PD-1)及其配体PD-L1的治疗方法。PD-1/PD-L1抑制剂在多种肿瘤中具有非常明显的临床获益和持久反应,但是整体反应率仍较低。研究发现PD-L1和肿瘤突变负荷可以预测免疫治疗效果,MSI-H/dMMR、TP53和KRAS等基因突变与免疫治疗疗效呈正相关;而MDM2/4、EGFR、ALK等基因则与免疫治疗效果呈负相关。

Tumor immunotherapy is a treatment method mainly for programmed cell death-1(PD-1)and its ligand PD-L1.PD-1/PD-L1 inhibitors have obvious clinical benefits and long-lasting responses in a variety of tumors.But overall response rates are still low.Studies show that PD-L1 and tumor mutation burden can predict the effect of immunotherapy.MSI-H/dMMR,TP53 and KRAS mutations are positively correlated with the effect of immunotherapy.While MDM2/4,EGFR,ALK and other genes are negatively correlated with the effect of immunotherapy.